Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Anti-CD19 chimeric antigen receptor T-cell immunotherapy (19CAR-T) has achieved impressive clinical results in adult and pediatric relapsed/refractory (r/r) B-lineage acute lymphoblastic leukemia (B-ALL). However, the application and effect of CAR-T therapy in B-ALL patients with extramedullary relapse are rarely issued even disqualified in some clinical trials. Here, we examined the efficacy of 19CAR-T in patients with both bone marrow and extramedullary involvement. Materials and methods: CAR-T cells were generated by transfection of primary human T lymphocytes with a lentiviral vector expressing anti-CD19 single chain antibody fragments (scFvs) with the cytoplasmic domains of 4-1BB and CD3ζ, and used to infuse patients diagnosed as having r/r B-ALL with extramedullary origination. Clinical responses were evaluated by the use of bone marrow aspiration, imaging, and flow cytometry. Results: Eight patients received 19CAR-T infusion and all attained complete remission (CR). Only one patient was bridged to hematopoietic stem cell transplantation (HSCT). Although three patients relapsed after infusion, they received 19/22CAR-T infusion sequentially and attained a second remission. To date, five patients are in continuous CR and all eight patients are still alive. The mean follow-up time was 21.9 months, while the 24-month estimated event-free survival is 51.4%. Conclusion: 19CAR-T therapy can lead to clinical remission for extramedullary relapsed pediatric B-ALL patients. However, the problem of CD19+ relapses after CAR-T remained to be solved. For patients relapsing after CAR-T, a second CAR-T therapy creates another opportunity for remission for subsequent HSCT.
Abstract
Purpose: Anti-CD19 chimeric antigen receptor T-cell immunotherapy (19CAR-T) has achieved impressive clinical results in adult and pediatric relapsed/refractory (r/r) B-lineage acute lymphoblastic leukemia (B-ALL). However, the application and effect of CAR-T therapy in B-ALL patients with extramedullary relapse are rarely issued even disqualified in some clinical trials. Here, we examined the efficacy of 19CAR-T in patients with both bone marrow and extramedullary involvement. Materials and methods: CAR-T cells were generated by transfection of primary human T lymphocytes with a lentiviral vector expressing anti-CD19 single chain antibody fragments (scFvs) with the cytoplasmic domains of 4-1BB and CD3ζ, and used to infuse patients diagnosed as having r/r B-ALL with extramedullary origination. Clinical responses were evaluated by the use of bone marrow aspiration, imaging, and flow cytometry. Results: Eight patients received 19CAR-T infusion and all attained complete remission (CR). Only one patient was bridged to hematopoietic stem cell transplantation (HSCT). Although three patients relapsed after infusion, they received 19/22CAR-T infusion sequentially and attained a second remission. To date, five patients are in continuous CR and all eight patients are still alive. The mean follow-up time was 21.9 months, while the 24-month estimated event-free survival is 51.4%. Conclusion: 19CAR-T therapy can lead to clinical remission for extramedullary relapsed pediatric B-ALL patients. However, the problem of CD19+ relapses after CAR-T remained to be solved. For patients relapsing after CAR-T, a second CAR-T therapy creates another opportunity for remission for subsequent HSCT.
참고문헌 (30)
- Heikamp EB, "Next-generation evaluation and treatment of pediatric acute lymphoblastic leukemia", J Pediatr, 203, pp.14~24 (2018)
- Pui CH, "Childhood acute lymphoblastic leukemia : progress through collaboration", J Clin Oncol, 33, pp.2938~2948 (2015)
- Ding LW, "Mutational profiling of acute lymphoblastic leukemia with testicular relapse", J Hematol Oncol, 10, pp.65~ (2017)
- Kosucu P, "Multiple relapses in extramedullary localization of acute lymphoblastic leukemia", Bratisl Lek Listy, 113, pp.46~49 (2012)
- Bhojwani D, "Relapsed childhood acute lymphoblastic leukaemia", Lancet Oncol, 14, pp.e205~e217 (2013)
- Kondoh T, "CD7 promotes extramedullary involvement of the B-cell acute lymphoblastic leukemia line Tanoue by enhancing integrin beta2-dependent cell adhesiveness", Int J Oncol, 45, pp.1073~1081 (2014)
- Sun W, "Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia : a therapeutic advances in childhood leukemia & lymphoma study", Leukemia, 32, pp.2316~2325 (2018)
- von Stackelberg A, "Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy : a retrospective analysis of the ALL-REZ BFM Study Group", Eur J Cancer, 47, pp.90~97 (2011)
- Gross G, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity", Proc Natl Acad Sci U S A, 86, pp.10024~10028 (1989)
- Srivastava S, "Engineering CAR-T cells : design concepts", Trends Immunol, 36, pp.494~502 (2015)
- Maude SL, "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia", N Engl J Med, 378, pp.439~448 (2018)
- Gardner RA, "Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults", Blood, 129, pp.3322~3331 (2017)
- Lee DW, "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults : a phase 1 dose-escalation trial", Lancet, 385, pp.517~528 (2015)
- Curran KJ, "Toxicity and response after CD19-specific CAR T-cell therapy in pediatric", young adult relapsed, Blood, pp.2019, 134[DOI]
- Lee DW, "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells", Biol Blood Marrow Transplant, 25, pp.625~638 (2019)
- Weng J, "A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia", J Hematol Oncol, 11, pp.25~ (2018)
- Pui CH, "A 50-year journey to cure childhood acute lymphoblastic leukemia", Semin Hematol, 50, pp.185~196 (2013)
- Kantarjian H, "Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia", N Engl J Med, 376, pp.836~847 (2017)
- Aldoss I, "Correlates of resistance and relapse during blinatumomab therapy for relapsed", refractory acute lymphoblastic leukemia, 2017, pp.92, 858~865
- Jabbour E, "Outcome of patients with relapsed", refractory acute lymphoblastic leukemia after blinatumomab failure : no change in the level of CD19 expression, 2018, pp.93, 371~374
- Chen X, "Treatment of testicular relapse of B-cell acute lymphoblastic leukemia with CD19-specific chimeric antigen receptor T cells", Clin Lymphoma Myeloma Leuk, 20, pp.366~370 (2020)
- Talekar MK, "Effect of chimeric antigen receptor-modified T(CAR-T)cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia(ALL)", J Clin Oncol, 35(15 Suppl), pp.10507~ (2017)
- Dai H, "Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia", Oncoimmunology, 4, pp.e1027469~ (2015)
- Jacoby E, "Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia", Am J Hematol, 93, pp.1485~1492 (2018)
- Schafer H, "Extramedullary relapses at uncommon sites after allogeneic stem cell transplantation", Bone Marrow Transplant, 26, pp.1133~1135 (2000)
- Santomasso BD, "Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia", Cancer Discov, 8, pp.958~971 (2018)
- Gust J, "Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells", Cancer Discov, 7, pp.1404~1419 (2017)
- Lee DW, "Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine", cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation, 2016, pp.128, 218~
- Park JH, "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia", N Engl J Med, 378, pp.449~459 (2018)
- Hay KA, "Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy", Blood, 133, pp.1652~1663 (2019)